AEMD
Aethlon Medical, Inc.
Healthcare — Medical Devices
Aethlon Medical, Inc., a medical therapeutic company, engages in developing novel immunotherapeutic devices in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device intended to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation, and other disease states. The company was founded in 1984 and is based in San Diego, California.
None
2 analysts
$6.63
+$0.11 (+1.69%)
Target:
$3.25
(-51.0%)
Price History
52-Week Range
Sign in to add AEMD to a watchlist or set price alerts.
Fundamentals
| Market Cap | $1.95M |
| P/E Ratio (TTM) | - |
| Forward P/E | -1.65 |
| EPS (TTM) | $-10.61 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -142.89% |
| Debt/Equity | 10.54 |
| Recommendation | None |
| Analyst Target | $3.25 |
| Analysts | 2 |
| Next Earnings | Aug 13, 2026 AMC |
| Indexes | - |
Technical Indicators
| RSI (14) | 13.2 |
| Beta | 1.32 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $27.40 |
| 52-Week Low | $0.78 |
| 50-Day Avg | $2.07 |
| 200-Day Avg | $3.35 |
| Avg Volume | 631.3K |
| Volume | 110.9K |
Performance Analysis
NEUTRALAEMD presents a mixed picture with both positive and negative indicators.
~
Trading at 22% of its 52-week range.
+
RSI at 13.2 signals oversold conditions — a bounce may be ahead.
+
Price is above both the 50-day and 200-day moving averages — strong uptrend.
~
Wall Street consensus is "none" from 2 analysts.
-
Average analyst target of $3.25 implies 51.0% downside.
Recent News
Loading news...
Last updated: Jun 30, 2026 21:07 UTC
Back to Screener Export Report